Please login (Members) to view content or
(Nonmembers) this article.
No votes yet
Research Highlights

Research Highlights 04-2000

Diane G. Cope
ONF 2000, 27(3), 435-438 DOI: 10.1188/00.ONF.435-438

Two separate studies have found promising results in combination Rituxan/CHOP chemotherapy for patients with non-Hodgkin lymphoma (NHL). Researchers from Roswell Park Memorial Institute reported three-year follow-up data in patients with low-grade or follicular NHL who received combination regimens.

  • Combination Rituxan/CHOP Chemotherapy for NHL Provides Prolonged Response Rates
  • Rituxan Shows improved Response in Chronic Lymphocytic Leukemia
  • Rituxan Shows Activity Against Multiple Myeloma
  • New Antibody Therapy Provides Remission in Some Patients With AML
  • Rituxan Shown to increase Responses in Non-Hodgkin’s
  • Lymphoma Adriamycin/Taxol Combination Shows Superiority Over FAC in Metastatic Breast Cancer
  • Weekly Combination Paclitaxel/Herceptin Therapy Effective in Metastatic Breast Cancer
  • Goserelin/Tamoxifen Reduces Recurrences in Premenopausal Patients With Breast Cancer
  • Weekly High-Dose Neoadjuvant Paclitaxel Effective in Advanced-Stage Breast Cancer
  • Anastfozoie Is as Effective as Tamoxifen for First-Line Therapy in Metastatic Breast Cancer

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or